Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.

Diabetes, obesity & metabolism - 1 May 2026

Shen Xingyu, Luo Shan, Zheng Jie, Chui Celine Sze Ling, Wong Ian Chi Kei, Wan Eric Yuk Fai, Schooling Catherine Mary, Au Yeung Shiu Lun

Abstract excerpt

AIMS: Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug-target Mendelian randomization (MR) design. MATERIALS AND METHODS: We identified genetic proxies of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinases
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Mendelian Randomization Analysis

Share to Metformin

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41755790
DOI: 10.1111/dom.70598
PMCID: PMC13071220

Genes

PRKAG1
GPD1
ACACB
ETFDH
PRKAA1
PRKAA2
PRKAB1
PRKAB2
PRKAG2
PRKAG3
SLC47A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.PMID 41755790Read ↗

Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.Semantic proximity Read ↗

Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysisSemantic proximity Read ↗

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Semantic proximity Read ↗

New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.Semantic proximity Read ↗

Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study.Semantic proximity Read ↗

Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK BiobankSemantic proximity Read ↗

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.Semantic proximity Read ↗

Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization studySemantic proximity Read ↗

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization studySemantic proximity Read ↗

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.Semantic proximity Read ↗

Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.